SS-31 targets the inner mitochondrial membrane directly via cardiolipin binding to stabilize cristae architecture and reduce ROS; MOTS-c is a mitochondria-derived peptide that acts as a nuclear-encoded metabolic regulator, mimicking exercise-induced AMPK activation.
Research reference only — all information on this page summarises peer-reviewed scientific literature and does not constitute medical advice. View full compound profiles: SS-31 · MOTS-c
Mechanism Comparison
SS-31 (D-Arg-Dmt-Lys-Phe-NH₂, also called elamipretide) is a cell-permeable, mitochondria-targeted antioxidant peptide. Its alternating aromatic-cationic structure drives selective accumulation at the inner mitochondrial membrane where it binds cardiolipin — the signature lipid of mitochondrial cristae. Cardiolipin binding stabilizes cristae morphology, preserves cytochrome c association, and reduces mitochondrial ROS generation under stress conditions. MOTS-c (Mitochondrial ORF of the 12S rRNA Type-C) is a 16-amino-acid peptide encoded by the mitochondrial genome, not the nuclear genome. It translocates to the nucleus upon metabolic stress and activates AMPK signalling, folate/methionine cycle modulation, and antioxidant response elements. While both peptides improve mitochondrial function in preclinical models, they operate at distinct anatomical sites (membrane vs. nuclear transcription) through entirely different mechanisms.
Side-by-Side Attributes
| Attribute | SS-31 | MOTS-c |
|---|---|---|
| Origin | Synthetic; designed by Szeto & Schiller | Endogenous; encoded in mitochondrial 12S rRNA |
| Structural class | Tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂); aromatic-cationic | 16-amino-acid peptide; mitochondria-derived |
| Primary target | Inner mitochondrial membrane cardiolipin | AMPK / nuclear gene expression (via mitochondria-to-nucleus signalling) |
| Mechanism | Cardiolipin stabilization → preserved cristae → reduced ROS + preserved ATP synthesis | AMPK activation → folate/methionine cycle → metabolic reprogramming; exercise-mimetic |
| Research models | Cardiac ischemia-reperfusion, renal disease, aging, muscle atrophy | Exercise physiology, metabolic disease, aging, obesity, insulin resistance |
| Dosing route in trials | Subcutaneous injection (elamipretide clinical trials) | Subcutaneous injection in rodent studies; human data limited |
| Human clinical data | Phase 2 data in heart failure (SPARCL), renal disease (ReCLAIM); Stealth Bio developed elamipretide | Limited; primarily preclinical rodent and in vitro; pilot human metabolic data emerging |
| FDA regulatory status | Investigational (elamipretide); no approved indication | Research compound only; no IND or approved indication |
| Key research strength | Most advanced mitochondria-targeted peptide in human trials; strong cardiac and renal data | Unique endogenous origin; potent exercise-mimetic and metabolic effects in aging models |
Key Research Points
- 1SS-31 works at the inner mitochondrial membrane by stabilizing cardiolipin, directly reducing ROS and preserving electron transport chain integrity; MOTS-c works upstream via AMPK-mediated nuclear transcription.
- 2SS-31 (as elamipretide) has the most advanced human clinical trial data of any mitochondria-targeted peptide, including Phase 2 trials in heart failure with preserved ejection fraction and primary mitochondrial myopathy.
- 3MOTS-c is unique as an endogenous mitochondria-encoded peptide — its circulating levels decline with age in rodent and human studies, supporting a physiological role in metabolic aging that SS-31 does not share.
- 4Preclinical aging research has used both peptides with documented improvements in muscle function, exercise capacity, and metabolic markers, but through mechanistically distinct pathways.
- 5Neither peptide has received FDA approval for any therapeutic indication; all human-use research should be understood in the context of investigational or early clinical-stage evidence.
Frequently Asked Questions
What is the difference between SS-31 and MOTS-c?
SS-31 (elamipretide) is a synthetic tetrapeptide that accumulates at the inner mitochondrial membrane and stabilizes cardiolipin to reduce oxidative stress and preserve ATP production. MOTS-c is a naturally occurring peptide encoded by the mitochondrial genome that acts as a metabolic messenger — translocating to the nucleus to activate AMPK signalling and gene programs associated with exercise adaptation and insulin sensitivity. They target different cellular compartments and activate different molecular pathways, though both ultimately support mitochondrial function.
Which has more human clinical trial data — SS-31 or MOTS-c?
SS-31 (as elamipretide, developed by Stealth BioTherapeutics) has substantially more human clinical trial data, including Phase 2 studies in heart failure with preserved ejection fraction (HFpEF), primary mitochondrial myopathy, and Barth syndrome. MOTS-c's human data is limited to observational studies and small pilot investigations; no Phase 2 randomized controlled trials have been completed.
Are SS-31 and MOTS-c studied together in any research models?
Combination studies of SS-31 and MOTS-c are rare in published literature. A small number of aging and exercise-biology reviews have discussed both peptides as part of a broader "mitochondrial peptide" or "exercise mimetic" framework. In preclinical aging models, both have been administered independently with complementary outcomes (mitochondrial quality via SS-31; metabolic reprogramming via MOTS-c), but formal head-to-head or combination dosing studies had not been published as of early 2026.
Full compound profile
SS-31
Full compound profile
MOTS-c